stem cell transplant-M.D. Anderson Cancer Center-peripheral T-cell lymphoma

This therapeutic regimen, evaluated in a Phase 2 clinical trial at M.D. Anderson Cancer Center, combines the anti-CD52 monoclonal antibody **alemtuzumab** (Campath-1H) with **autologous or allogeneic stem cell transplantation** (SCT) for the treatment of **peripheral T-cell lymphoma** (PTCL). Alemtuzumab is utilized for in-vivo purging of T-cells prior to autologous SCT and as part of the conditioning regimen for allogeneic SCT to reduce the risk of graft-versus-host disease (GVHD) and eliminate minimal residual disease. The protocol also incorporates a multi-agent conditioning regimen including carmustine (BCNU), fludarabine, cyclophosphamide, cytarabine, etoposide, and melphalan, supported by growth factors such as G-CSF and GM-CSF. This intensive approach aims to improve outcomes in PTCL, an aggressive form of non-Hodgkin lymphoma with a typically poor prognosis.

Brand names

Campath

Other names

Campath-1H and Stem Cell Transplantation for T-Cell LymphomaCampath1H and Stem Cell Transplantation for T-Cell LymphomaCampath 1H and Stem Cell Transplantation for T-Cell LymphomaAlemtuzumab + SCT for PTCLCampath-1HCampath1HCampath 1Halemtuzumab